Semaglutide 0.5 mg: where this dose sits in Wegovy treatment

Why does the Wegovy schedule even have a 0.5 mg step?

The titration ladder for semaglutide injection was designed around tolerability, not speed. Starting at a low dose and stepping up gradually gives your gastrointestinal system time to adapt. Nausea, the most commonly reported early side effect, tends to peak when the dose goes up and then settle, sometimes within days, sometimes over a couple of weeks. Moving from 0.25 mg to 0.5 mg after four weeks is the point where many people notice the GI effects most sharply for the first time, simply because 0.25 mg is so small it often passes without much disruption at all.

The full semaglutide dose progression runs 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching 2.4 mg as the standard maintenance level. Each increment is roughly four weeks apart, though your prescriber may slow that pace if side effects are significant. At 0.5 mg you are still very much in the adjustment phase; the clinical effects on appetite and body weight build progressively as the dose rises. People sometimes feel disheartened if they are not seeing much change at 0.5 mg, that is completely normal, and worth knowing in advance rather than after the fact. If you want to understand what comes next, our guide to semaglutide 1 mg explains what to expect when you step up to that level.

The Wegovy treatment overview explains the full mechanism and what to expect across the whole course, which can help frame where this early step fits.

Is semaglutide 0.5 mg the same concentration as Ozempic 0.5 mg?

This is one of the most common points of confusion. Semaglutide is the active ingredient in both Wegovy and Ozempic, so numerically the same number appears on both products. But they are not interchangeable. Ozempic 0.5 mg is a dose used for type 2 diabetes management; the MHRA licenses it for that purpose, not for weight loss. Wegovy's 0.5 mg step is part of a weight-management titration ladder, given under a different licensed indication entirely.

The practical implication: if someone offers you a 0.5 mg semaglutide pen without being clear whether it is Wegovy or Ozempic, that distinction matters. A medicine supplied for a different licensed indication, sourced outside the regulated supply chain, creates real clinical risk. The guide to getting Wegovy through a legitimate route covers what a compliant supply chain actually looks like and what red flags to watch for. The MHRA has issued repeated warnings about semaglutide products sold online without clinical oversight, the Yellow Card scheme exists partly so patients can flag suspect sellers.

Stick to the licensed product, sourced from a pharmacy you can verify on the GPhC register, prescribed following a clinical assessment. That is not bureaucracy for its own sake; it is what keeps the supply chain safe.

What side effects tend to appear around the 0.5 mg stage?

The dose-increase moments are when side effects are most likely to surface. At 0.5 mg (whether you are arriving here for the first time or returning to it after a break) nausea is the most frequently reported issue, followed by constipation, loose stools, indigestion and occasional dizziness. Most of these are mild to moderate and tend to ease as your body settles at the new level. Eating smaller portions, avoiding very fatty or spicy meals, and staying well hydrated all help.

A few symptoms warrant prompt medical attention at any dose: severe stomach pain that reaches through to the back can be a sign of pancreatitis, which the MHRA flagged as an infrequent but serious risk in a Drug Safety Update published January 2026. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing) also need urgent assessment. Your Patient Information Leaflet lists everything in full; read it when your pen arrives rather than if something goes wrong.

If you have questions about a specific symptom at this dose, the frequently asked questions section covers common concerns, or you can reach out through the support team, who are available seven days a week.

Can you stay at 0.5 mg long-term, or does the dose have to keep rising?

Clinically, the 2.4 mg maintenance dose is where the evidence for meaningful weight loss is strongest, the STEP 1 trial, which underpins Wegovy's licence, was conducted at that level and showed an average body-weight reduction of around 15% over 68 weeks. Staying at 0.5 mg indefinitely is not part of the licensed treatment plan for weight management, though your prescriber may slow titration if your tolerance genuinely needs more time at each step.

The distinction matters because the range of Wegovy doses now extends beyond 2.4 mg: the MHRA approved a 7.2 mg maintenance dose in January 2026, with a dedicated single-dose pen following in April 2026. That means the gap between 0.5 mg and what some patients eventually reach is wider than it used to be, and if you are using a compounded or reconstituted product at higher concentrations, our semaglutide mixing chart for the 10 mg vial sets out the preparation guidance clearly. Where you end up on that spectrum is a clinical conversation, not a patient-led choice. If you are weighing up whether to start treatment or wondering about the broader range of weight-loss options, speaking to a prescriber is the step that makes sense.

At nume, a GPhC-registered prescriber reads every consultation personally (a real clinician, not a form processor) and can advise on whether your current dose and pace of titration are right for you. Speak to our prescribers to start that conversation.